Drug Shortage Report for TEVA-RIVAROXABAN
Report ID | 219671 |
Drug Identification Number | 02507218 |
Brand name | TEVA-RIVAROXABAN |
Common or Proper name | RIVAROXABAN 15MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | RIVAROXABAN |
Strength(s) | 15MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 3x10 |
ATC code | B01AF |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-02-14 |
Estimated end date | 2024-05-31 |
Actual end date | 2024-05-31 |
Shortage status | Resolved |
Updated date | 2024-07-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2024-02-15 | English | Compare |
v2 | 2024-02-15 | French | Compare |
v3 | 2024-07-03 | English | Compare |
v4 | 2024-07-03 | French | Compare |
Showing 1 to 4 of 4